Studies related to Fever and Pelargonium sidoides

The Efficacy Of Pelargonium Sidoides In The Treatment Of Upper Respiratory Tract Infections In Children With Transient Hypogammaglobulinemia Of Infancy

In children with upper respiratory tract infections associated with transient hypogammaglobulinemia of infancy, supplementation of 1.5mL (10 drops) of EPs-7630 thrice daily for a week was able to significantly benefit nasal congestion (71.4% of treatment having no congestion relative to 21.5% of placebo) and appetite. Fever, cough, well being, and myalgia were not affected.

Pelargonium Sidoides Preparation (EPs 7630) In The Treatment Of Acute Bronchitis In Adults And Children

Two weeks supplementation of EPs7630 to persons of all ages (30 drops thrice daily for adults, but 20 drops thrice daily for those between 6-12 and 10 drops thrice daily for those younger than 6) was able to significantly reduce overall symptoms as assessed by the BSS by around 86% with 68% of the sample reporting more than a 5 point reduction.

Most other comorbidities such as fever, fatigue, and headache were reduced in the range of 80-94.6%. Rhonchi (93.1% remission) chest pain during cough (94.1%), and shortness of breath (93.2%), but cough was only abolished in 56.2% of persons.

Efficacy And Safety Of An Extract Of Pelargonium Sidoides (EPs 7630) In Adults With Acute Bronchitis. A Randomised, Double-blind, Placebo-controlled Trial

Thirty drops (4.5mL) of Eps7630 thrice daily for a week in adults with acute bronchitis around the time of meals was associated with a greater decrease of overall symptoms as assessed by the BSS rating scale (70% reduction in symptoms) relative to placebo (40%) with symptom reduction occurring in about three days time.

EPs7630 was also more effective at causing an overall rating of less than three on the 10 point rating scale (64.4% relative to 37.9%) and at inducing a 7 point reduction within the week (43.3% relative to 23% in placebo).

After 7 days, there was abolishment of rhonchi (77.1%), coughing (83.8%) fatigue (65.1%), headache (75-81.7%), and fever (96.9%) in treatment, all more than placebo.

Efficacy Of A Pelargonium Sidoides Preparation In Patients With The Common Cold: A Randomized, Double Blind, Placebo-controlled Clinical Trial

In adults with cold symptoms for 24-48 hours, supplementation of EPs7630 at 30 drops (1.5mL) thrice daily for up to 10 days and assessed by total symptoms and cold intensity rating scales noted that supplementation was assocatiated with twice the reduction in symptoms than was placebo, and after 10 days 78.8% of persons given the supplement were seen as clinically cured (relative to 31.4% of placebo).

Treatment Of Acute Bronchitis In Adults With A Pelargonium Sidoides Preparation (EPs 7630): A Randomized, Double-blind, Placebo-controlled Trial

30 drops (4.5mL) of EPs7630 thrice daily for a week in adults with acute bronchitis was associated with significant reductions in symptoms as assessed by the BSS rating scale. There was also a greater change of a 5 point reduction in the treatment group (90.6%) rather than placebo (51.7%) and reported rapid recovery (90.6% relative to 41.7%); there were significantly more remissions of cough (31.3%), rhonchi (91%)

Can The Pelargonium Sidoides Root Extract EPs® 7630 Prevent Asthma Attacks During Viral Infections Of The Upper Respiratory Tract In Children

In asthmatic children with viral URTIs, supplementation of the standard doses of EPs7630 was able to reduce nasal congestion and cough but not fever nor muscle aches. There was a significant reduction in asthmatic attacks in the sick group treated with EPs7630 relative to placebo.

Treatment Of Acute Bronchitis With A Liquid Herbal Drug Preparation From Pelargonium Sidoides (EPs 7630): A Randomised, Double-blind, Placebo-controlled, Multicentre Study

In adult patients with acute bronchitis given 30 drops of EPs7630 thrice daily for a period of one week, symptoms of acute bronchitis (BSS) was able to increase complete remission on day seven to 45.4% of the treatment group (over 6.4% of the placebo) as assessed by physicians, and 89.8% and 65.1% self-reported complete or major recovery (more 'complete' recovery in treatment). Most marked improvement was in cough, where only 11.9% of placebo reported complete recovery while 51.9% of treatment did after seven days.

EPs 7630-solution--an Effective Therapeutic Option In Acute And Exacerbating Bronchitis

EPs7630 at 30 drops thrice daily in persons with bronchitis (either acute, or chronic bronchitis experienced an exacerbation) over a week was associated with improvements on all symptoms of bronchitis to a level greater than placebo. Symptoms appeared to be improved within 2 days of supplementation, and after 7 days 92.7% of the treatment group reported satisfaction with treatment.

EPs 7630 Improves Acute Bronchitic Symptoms And Shortens Time To Remission. Results Of A Randomised, Double-blind, Placebo-controlled, Multicentre Trial

In adult outpatients with acute bronchitis given the standard 30 drops of EPs7630 thrice daily for a period of seven days, there were significantly improved symptoms on all parameters of the BSS and secondary outcome variables with particular improvement in fatigue and coughs; days off from work was reduced secondary to helping cure acute bronchitis.